Teva Pharmaceutical Industries Limited · TASE:TEVA
Teva Pharmaceutical Industries — Merger or Acquisition (October 2023)
21 slides from Teva Pharmaceutical Industries's merger presentation, Oct 4, 2023
Slide 1: Teva & Sanofi Transformative Anti-TL1A Collaboration
Teva & Sanofi Transformative Anti-TL1A Collaboration October 4, 2023
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainti
Slide 3: Agenda
Agenda Strategic Rationale Clinical Program Update Financial Overview Q&A Richard Francis Eric Hughes, MD, PhD Eli Kalif Teva Executive President & EVP, Global R&D & EVP, Management Chief Executive Officer Chief Medical Officer Chief Financial Officer |3|
Slide 4: Transformative Collaboration Accelerating Innovation and Pivot to Growth
Transformative Collaboration Accelerating Innovation and Pivot to Growth Richard Francis President and Chief Executive Officer |4|
Slide 5: Executing Teva's Pivot to Growth Strategy
Executing Teva’s Pivot to Growth Strategy Deliver on Step up Sustain generics Focus our growth engines innovation powerhouse business • AUSTEDO to reach $1.2 billion • Accelerated development of • Focus on high-value generics • Teva API (TAPI) standalone in 2023; Reaffirming Goal to Innovative late-
Slide 6: Transformative Collaboration to Accelerate Full Potential of Anti-TL1A (TEV '574)
Transformative Collaboration to Accelerate Full Potential of Anti-TL1A (TEV '574) 50/50 worldwide joint collaboration with global immunology leader to maximize value of Teva’s anti-TL1A asset • Potential for best-in-class in inflammatory bowel disease (IBD), with significant unmet medical need • Opt
Slide 7: Anti-TL1A, a Key Late-Stage Asset In a Promising Pipeline
Anti-TL1A, a Key Late-Stage Asset In a Promising Pipeline Preclinical Phase 1 Phase 2 Phase 3 TEV ’278 TEV ’408 Anti-TL1A Olanzapine LAI Oncology Gastrointestinal (TEV ’574) (TEV ’749) Ulcerative Colitis Schizophrenia TEV ’279 Crohn's Disease Neuroscience TEV ’2861 ICS/SABA Multiple System (TEV ’248
Slide 8: Revenue Potential Maximized Through Collaboration
Revenue Potential Maximized Through Collaboration Large underserved market Expected anti-TL1A competitive profile Unmet patient population Market potential 1 Promising pre-clinical data Showcasing potential to be best-in-class >4M1 diagnosed patients $28B+ 2 Well-characterized safety and ADA profile
Slide 9: Anti-TL1A Program Strengthened through Collaboration with Sanofi
Anti-TL1A Program Strengthened through Collaboration with Sanofi Expanding Broadening Scope Accelerating Commercial for Indication Innovation Accelerates Potential Expansion Pivot to Growth • Partnership with a • Anchor asset in • Sanofi uniquely global leader in inflammatory bowel positioned to max
Slide 10: TEV '574 (Anti-TL1A): Clinical Program Update
TEV ‘574 (Anti-TL1A): Clinical Program Update Dr. Eric Hughes, MD, PhD Executive Vice President, Global R&D & Chief Medical Officer | 10 |
Slide 11: TL1A Targeting is a Validated Mechanism of Action
TL1A Targeting is a Validated Mechanism of Action TL1A key role in inflammatory cascade and fibrosis in the gut through its DR3 receptor TL1A targeting already demonstrated in in-human study with potential relevance in wide range of auto-immune indications | 11 | DR3: Receptor involved in pro-inflam
Slide 12: Antibody Designed for Selective Binding
Antibody Designed for Selective Binding TL1A binding to two receptors TEV '574 carefully designed to preferentially block DR3 and not DcR3 DR3 receptor DcR3 decoy receptor TEV '574 TL1A Xray Desirable to block Desirable to retain structure • Human antibody with sub-nM affinity TEV '574 binds for TL1
Slide 13: High Selectivity to DR3 and High Potency Confirmed in vitro
High Selectivity to DR3 and High Potency Confirmed in vitro TEV '574 more selective than comparative reagent1, 2 TEV '574 more potent than comparative reagent1, 6 TEV '574 DR3:DcR3 Anti-TL1A #11, 3 DR3:DcR3 TEV '574 vs. Anti-TL1A #21, 7 100 100 150 (TL1A-induced response) % completion for TL1a 100 %
Slide 14: Strong TL1A inhibition confirmed in animal model
Strong TL1A inhibition confirmed in animal model Rapid and sustained clearance of free TL1A in non-human primate study 125 Non-human primates received a single dose (n=4) Free TL1A in serum (pg/mL) 100 75 TEV ’574 rapidly reduced free TL1A 50 Prolonged reduction to at least 14 days 25 Inhibition of
Slide 15: Ambition to Obtain Best-in-Class Profile
Ambition to Obtain Best-in-Class Profile • Greater potency vs. comparative reagents in in vitro assays1 Best-in-class preclinical profile • >100x selectivity for DR3 (vs. decoy) • Reduction of fibrosis in animal models2 Favorable safety and tolerability • Comparable adverse events incidence vs. plac
Slide 16: Next Milestones on our Key Innovative Pipeline Assets
Next Milestones on our Key Innovative Pipeline Assets Anti-TL1A Phase II interim analysis H2 2024 TEV ’574 Olanzapine LAI Adult Phase III results H1 2025 TEV ’749 Anti-IL15 Phase I FIH SAD/MAD HV results H2 2024 TEV ’408 Anti-PD1-IL2 First patient enrolled in Phase I trial H1 2024 TEV ’278 ICS/SABA
Slide 17: Financial Overview
Financial Overview Eli Kalif Executive Vice President, Chief Financial Officer | 17 |
Slide 18: 50/50 Worldwide Joint Collaboration Maximizes Alignment with Strategic Objectives
50/50 Worldwide Joint Collaboration Maximizes Alignment with Strategic Objectives Overall economics accelerated and enhanced by Key details of deal structure 50/501 worldwide profit share Upfront $500 million in cash • Outcome of an extensive process where a range of strategic options were considere
Slide 19: Clear Capital Allocation Strategy
Clear Capital Allocation Strategy Meeting our commitments while funding growth Debt repayment and 1 net working capital enhancement Cash flow from operations Investment in our growth engines 2 (AUSTEDO, AJOVY®, UZEDY, etc.) Portfolio optimization Investment in R&D and 3 business development | 19 |
Slide 20: Anti-TL1A Collaboration Progresses
50/50 worldwide joint collaboration with global immunology leader to accelerate innovation and Pivot to Growth strategy Ability to leverage partnership to maximize asset value to Teva with pipeline-in-a-product potential Anti-TL1A Collaboration Optimal structure that delivers substantial upfront and
Slide 21: Q&A
Q&A | 21 |
Teva Pharmaceutical Industries — Merger or Acquisition (October 2023) on 6ix